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ABSTRACT  
Background: Celiac disease (CD) is associated with an increased risk of developing epilepsy, a 
risk that persists after CD diagnosis. A significant proportion of CD patients have persistent 
villous atrophy (VA) on follow-up biopsy. This study¶VREMHFWLYH was to determine whether 
persistent VA on follow-up biopsy affects long-term epilepsy risk and epilepsy-related hospital 
emergency admissions.  
Methods: Nationwide Cohort Study. We identified all people in Sweden with histological 
evidence of CD who underwent a follow-up small intestinal biopsy (1969-2008). We compared 
those with persistent VA to those who showed histological improvement, assessing the 
development of epilepsy and related emergency hospital admissions (defined according to 
relevant ICD codes in the Swedish Patient Register). Cox regression analysis was used to assess 
outcome measures. 
Results: Of 7590 people with CD who had a follow-up biopsy, VA was present in 43%. The 
presence of persistent VA was significantly associated with a reduced risk of developing newly-
diagnosed epilepsy (hazard ratio [HR] 0.61; 95% confidence interval [CI] 0.38±0.98). On 
stratified analysis this effect was primarily amongst males (HR 0.35; 95 CI 0.15±0.80).  Among 
the 58 CD patients with a prior diagnosis of epilepsy, those with persistent VA were less likely 
to visit an emergency department with epilepsy (HR 0.37; 95%CI 0.09-1.09). 
Conclusions: In a population-based study of CD individuals, persisting VA on follow up biopsy 
was associated with reduced future risk of developing epilepsy but did not influence emergency 
epilepsy-related hospital admissions. Mechanisms as to why persistent VA confers this benefit 
requires further exploration.    
  
INTRODUCTION  
Celiac disease (CD) is an immune-mediated enteropathy, which has a prevalence of 1% in 
Western populations.[1, 2] It occurs in genetically susceptible individuals following exposure to 
dietary gluten. Strict adherence to a gluten-free diet (GFD) is the mainstay of treatment, which 
can reduce the risk of complications such as lymphoma, osteoporosis and micronutrient 
deficiencies.[3]  
Neurological conditions such as cerebellar ataxia,[4] peripheral neuropathy,[5] and headache[6] 
are all recognised extraintestinal manifestations associated with CD. Another important 
neurological disorder that has been examined is epilepsy. Previous work has shown large 
variability in the prevalence and incidence of epilepsy in CD (0-7.2%),[7-9] with our previous 
population-based study demonstrating a moderately increased risk (HR =1.42; 95% confidence 
interval [CI] = 1.24±1.62).[10] Potential underlying pathophysiological mechanisms for this 
association have been described previously in children in celiac disease, epilepsy and cerebral 
calcifications (CEC) syndrome, however uncertainty exists about these exact mechanisms in 
adults.[11] 
Follow-up biopsy has emerged as a potentially important approach to risk-stratify CD patients 
with regards to long-term prognosis. The rates of persistent villous atrophy (VA) are variable in 
the literature, occurring in > 30% of CD patients in most series,[12-14] with persisting VA 
inversely correlating with GFD adherence.[13, 15, 16] Although persistent VA does not impact 
overall mortality in CD, it may influence morbidity and be a factor explaining heterogeneity in 
previous epilepsy and CD studies.[17]. Performing a follow-up biopsy was historically 
considered standard-of-FDUHWRFRQ¿UP healing after adoption of a gluten-free diet.[18] However, 
the practice has subsequently declined due to the availability of serology data, which normalizes 
after elimination of dietary gluten.[19] This had led to recent guidelines no longer explicitly 
mandating a follow-up biopsy.[2, 20] 
  
The study examines whether persistent VA, as compared with mucosal healing is associated with 
an increased risk of developing newly diagnosed epilepsy among people with CD. In addition, 
we explore whether mucosal healing influences future epilepsy-related hospital emergency 
admissions in those with known epilepsy at the time of follow-up biopsy.   
 
METHODS 
Identification of individuals with CD 
During the years 2006±2008 we queried all pathology departments in Sweden (n = 28) for 
reports of VA, as identified by SnoMed codes. Details regarding this database have been 
published previously.[21] In brief, VA was identified by Swedish pathologists and a prior 
validation study demonstrated that among individuals identified via these histology codes, a 
clinical diagnosis of CD was present in 95%; alternative/comorbid diagnoses were rare (with 
inflammatory bowel disease, the most common comorbidity, present in 0.3% of 1,534 manually 
reviewed patient records).[21] 
The individuals in this analysis are those with CD who underwent more than one duodenal 
biopsy; they therefore represent a subset of all CD patients, who were included in our earlier 
study that found an increased risk of epilepsy in CD.[10] We identified those people with CD 
who underwent follow-up biopsy between 6 months and 5 years after initial CD diagnosis. Those 
who had a modified Marsh histopathology score[22] of 3 were classified as having persistent 
VA, while those with a less severe score were classified as healed. As reported previously, 
among a subset of patients where serologic data was available, villous atrophy was more 
common among those with persistently elevated celiac disease serologies (62%) compared to 
those with serologic normalization (21%).[17] 
 
  
Identification of individuals with Epilepsy and hospital emergency admissions 
Epilepsy was defined according to relevant International Classification of Diseases (ICD) codes 
in the Swedish National Patient Register[23]; our definition of epilepsy did not include status 
epilepticus or febrile convulsions (ICD-7: 353 except for 353.2; ICD-8: 345 except for 345.2; 
ICD-9: 345 except for 345Q; ICD-10: G40). The Swedish National Patient Register includes 
inpatient diagnoses from parts of Sweden since 1964 (nationwide since 1987), as well as 
hospital-based outpatient care since 2001. Emergency hospital admissions for epilepsy were 
defined also using relevant ICD codes in the Swedish Patient Register for epilepsy but also 
including status epilepticus (ICD-8: 345.2; ICD-9: 345Q, and ICD-10: G41) in patients with an 
earlier diagnosis of epilepsy.  
 
Statistical considerations 
We used Cox proportional hazard models to compare the risk of developing epilepsy among 
those with persistent VA versus those with mucosal healing on follow-up biopsy. In this 
analysis, the observation time (i.e., time at risk) started on the day of the follow-up biopsy and 
ended on the date of developing epilepsy, death, emigration or December 31, 2009, whichever 
occurred first. In this analysis we chose a priori the following covariates in the model: age at 
follow-up biopsy, gender, duration of CD at the time of follow-up biopsy, educational attainment 
(or in the case of children the highest educational attainment between the parents) and calendar 
period of follow-up biopsy.  
Because the risk of sequelae in CD (including mortality and morbidity) changes over time,[24] 
we tested the proportional hazards by recalculating the association between VA and the 
development of epilepsy during the following 3 pre-specified time strata: <1 year, 1±5 years, and 
!\HDUVDIWHUWKHSDWLHQW¶VIROORZ-up biopsy. We then performed stratified analysis by age, 
  
gender, and calendar period of follow-up biopsy.  
Analysis of emergency hospital related admissions for epilepsy was undertaken using Cox 
proportional hazard models. This analysis included all patients who were known to already have 
epilepsy at the time of follow-up biopsy. In addition to a Cox model measuring the risk of any 
emergency visit for epilepsy, we also assessed the association between persistent VA and the rate 
of emergency department visits among these individuals in the five years following their follow-
up biopsy. For this latter model we calculated rate ratios using Poisson regression among 
patients with known epilepsy at the time of their follow-up biopsy who had at least 5 years of 
observation time after that date.   
 
We used SAS version 9.3 (Cary, NC) for statistical analyses. We report risk estimates as hazard 
ratios (HR) and corresponding 95% confidence intervals (CI). All reported p values are two-
sided. This study was approved by the Research Ethics Committee of the Karolinska Institute on 
June 14th, 2006. $FFRUGLQJWRWKHERDUG¶VGHFLVLRQQRVWXG\SDUWLFLSDQWZDVFRQWDFWHGDVWKH
study is strictly register-based.[25]  
 
RESULTS 
Characteristics of patients who underwent follow-up biopsy 
Of 29,096 people with CD, 7648 (26%) underwent a follow-up biopsy between 6 months and 5 
years after their initial CD diagnosis. 58 of these individuals were known to have epilepsy at the 
time of follow up biopsy, leaving 7,590 remaining (Table 1). The median (interquartile range) 
age of CD diagnosis was 25 (3± 51) years and the median (interquartile range) age of follow-up 
biopsy was 26.8 (5±52) years. Nearly half of the patients (45%) were younger than 20 years at 
  
the time of follow-up biopsy.  Most patients (63%) were female and 45% of patients had follow-
up biopsy between 1 and 2 years after the CD diagnosis.  A previous analysis of this cohort 
found that those CD patients who had a follow-up biopsy differed slightly from those who did 
not; they were diagnosed with CD at a younger age (mean 28.4 vs 33.4 years, P<0.0001), and 
had a slightly greater female predominance (63% vs 61%, P= 0.0017).[17] 
Patients were followed up for a median (interquartile range) of 8.9 (5.4±14.1) years after follow-
up biopsy. Most patients (53%) had a follow-up biopsy after the year 2000. Of the 7,590 people 
who did not have epilepsy at the time follow-up biopsy, 3295 (43%) had persistent VA. 
Risk of developing Epilepsy 
There were 75 new diagnoses of epilepsy during the observation period after follow-up biopsy. 
The mean/median (SD) time from follow-up biopsy to epilepsy diagnosis in these patients was 
7.1/6.2 (5.5) years. Quantifications of the association between persistent VA and epilepsy 
stratified by gender, age, and calendar period are shown in Table 2. Persistent VA was associated 
with a reduced risk of developing epilepsy (HR 0.61; 95% CI 0.38±0.98), as compared to those 
with mucosal healing. This effect was primarily among males (HR 0.35; 95% CI 0.15-0.80) and 
there was no significant association between persistent VA and epilepsy among females (HR 
0.85; 95% CI 0.46-1.57). To test the robustness of our results a sensitivity analysis was 
performed using patients that had at least 2 interactions with Swedish health care due to a 
diagnosis of epilepsy. This demonstrated similar results (HR 0.57; 95% CI 0.33-1.01), however 
findings were just short of statistical significance (p=0.0532). The low number of events for 
³SDUWLDODQGJHQHUDOL]HG-RWKHU´ epilepsy subtypes in our cohort precluded any analysis using 
epilepsy subtypes. 
 
On time-stratified analysis, the reduced risk of epilepsy was most pronounced in the first year 
after follow-up biopsy (HR 0.36; 95%CI 0.07-1.74), though this was not statistically significant. 
  
The point estimates for the subsequent time strata were similar to each other (1-5 years: HR 0.66; 
>5 years: HR 0.64). A test for heterogeneity did not find that these three risk estimates differed 
significantly between time strata (p=0.78). 
 
Persistent VA and Epilepsy related emergency hospital admissions  
58 people with CD had an established diagnosis of epilepsy at the time of follow up biopsy. 
Those with persistent VA were less likely to visit an emergency department with epilepsy related 
problems, although not meeting statistical significance (HR 0.37; 95% CI 0.09-1.09, p=0.1605). 
When examining the rate of emergency department visits for epilepsy over a 5-year period, we 
identified 37 patients with a previous diagnosis of epilepsy who had 5 years of follow-up 
observation time. Among those with mucosal healing, the mean number of emergency visits over 
5 years was 0.57, compared to 0.44 among those with persistent VA (Rate ratio for those with 
persistent VA compared to those with healing 0.51; 95%CI 0.13-2.02).  
 
DISCUSSION 
In this population-based database of people with CD who underwent a follow-up biopsy, there 
was a reduced risk of developing epilepsy among those with persistent VA compared to those 
with mucosal healing. This finding was primarily amongst males. No significant difference in 
emergency hospital admissions for epilepsy was identified in those with persistent VA. 
 
These findings contrast our original hypothesis. We had hypothesized that persistent VA would 
be associated with an increased risk of future epilepsy and influence hospital admissions. This 
hypothesis was based on the observation that CD patients develop epilepsy at a greater rate than 
would be expected in the general population.[10] It seemed plausible that the autoimmune 
  
reaction inherent to CD would also increase epilepsy risk, with intestinal permeability potentially 
influencing blood-brain barrier permeability as has been reported in other neurological 
disorders.[26, 27] However, our findings suggest the mechanisms of mucosal injury and the 
chronic inflammation may be protective to developing epilepsy. TNF-alpha and the neuropeptide 
Ghrelin are two inflammatory mediators in CD that could have influenced outcomes. [28, 29] 
TNF-alpha is recognised to inhibit seizures in mice and Ghrelin has been shown to have 
anticonvulsant properties, which could have conferred protection to those not achieving mucosal 
healing.[30, 31]  
 
An alternative explanation is that a diagnosis of epilepsy is more frequently sought out and 
detected amongst those with mucosal healing, who better adhere to a GFD. It may be that 
individuals who follow SK\VLFLDQ¶V advice in this regard are more likely to seek medical 
attention for minor symptoms (including possible convulsions/epilepsy), when compared to non-
adherent individuals (with persistent VA) who may defer consultations. Other factors may also 
have influenced outcomes.  Previous work has shown that although adhering to a GFD can 
induce mucosal healing, it can lead to an increase in body weight.[32, 33] As weight change has 
been shown to influence other conditions such as breast cancer and type 2 diabetes, it may be 
that that weight gain is adversely influencing neurological processes and inflammation.[34-36]  
 
Another possibility is that patients with persistent VA on a first follow-up biopsy may not reflect 
long-term mucosal healing rates. In a study of patients undergoing serial small intestinal biopsy, 
the prevalence of mucosal healing was greater at 5 years (66%) than at 3 years (34%), suggesting 
that some individuals gradually heal over subsequent years.[15] In this population-based study, 
the prevalence of persistent VA was similar among those whose follow-up biopsy was performed 
1±2 years after diagnosis and 2±5 years after diagnosis[37], suggesting that gradual mucosal 
  
healing is not a widespread phenomenon at least within this timeframe. Another potential 
explanation is that patients undergoing follow-up biopsy may represent a healthier subset of 
patients with CD compared to those who did not, which may have been deferred due to medical 
comorbidities. Supporting this notion is our previously reported finding that overall mortality 
risk of individuals who underwent follow-up biopsy was slightly lower than those who did not 
have follow-up biopsy.[17] Although our study population had a large proportion of adults, the 
results were similar in both children and adult populations. These findings could suggest a 
shared underlying pathological mechanism between epilepsy and CD in both groups.   
 
This is the first study to our knowledge investigating the risk of epilepsy according to follow-up 
histology in CD. This study has several strengths, including its population-based design and the 
independent ascertainment of cases from national health registers. The Swedish National Patient 
Register has been validated repeatedly, and the majority of diagnoses have a high positive 
predictive value (85±95%).[23] Furthermore, CD was identified through biopsy records showing 
VA. During the study period, biopsy remained the gold standard for diagnosis in both children 
and adults, and 6% of all pediatricians and gastroenterologists in Sweden reported performing 
a small intestinal biopsy before diagnosis.[21] A patient chart review found that 95% of all 
samples with VA represented CD, a higher positive predictive value than physician-assigned 
diagnosis for CD in the Swedish National Patient register.[38] In addition, VA in Sweden is 
rarely explained by diagnoses other than CD (0.3% of individuals with VA had inflammatory 
bowel disease).[21] Although positive CD serology was not included within the definition of 
CD, it has been demonstrated that 88% of those with available CD serology data have positive 
antibodies at the time of first biopsy.[21] 
 
This study is limited by a lack of data regarding several important risk factors for epilepsy 
including previous head trauma, central nervous system infections and tumours.[39] Our ability 
  
to determine risk factors for both of CD and epilepsy was limited to ascertainment of age, 
gender, and histological outcomes. We therefore could not adjust for the previously highlighted 
risk factors that could have influenced our results. Our analysis of emergency department visits 
was limited by the small number of patients who developed epilepsy prior to follow-up biopsy, 
raising the possibility that we had insufficient power to detect whether healing is associated with 
this outcome.  
 
In conclusion, this analysis of more than 7,000 patients with CD undergoing follow-up biopsy 
found that persistent VA was associated with a significant reduction in subsequently developing 
epilepsy. Future work should investigate novel biomarkers of inflammation in CD that may 
impact epilepsy risk. 
 
Acknowledgements: JFL was supported by grants from The Swedish Society of Medicine, the 
Swedish Research Council ± Medicine (522-2A09-195), and the Swedish Celiac Society. 
Disclosures: None  
Funding Support: This project was supported by grants from the Swedish Society of Medicine 
and the Stockholm County Council.  
 
  
REFERENCES 
[1]. Mustalahti K, Catassi C, Reunanen A, et al. The prevalence of celiac disease in Europe: 
results of a centralized, international mass screening project. Ann Med. 2010 42: 587-595. 
[2]. Ludvigsson JF, Bai JC, Biagi F, et al. Diagnosis and management of adult coeliac 
disease: guidelines from the British Society of Gastroenterology. Gut. 2014 63: 1210-1228. 
[3]. Mooney PD, Hadjivassiliou M, Sanders DS. Coeliac disease. BMJ. 2014 348: g1561. 
[4]. Hadjivassiliou M, Sanders DS, Woodroofe N, Williamson C, Grunewald RA. Gluten 
ataxia. Cerebellum. 2008 7: 494-498. 
[5]. Ludvigsson JF, Olsson T, Ekbom A, Montgomery SM. A population-based study of 
coeliac disease, neurodegenerative and neuroinflammatory diseases. Aliment Pharmacol Ther. 
2007 25: 1317-1327. 
[6]. Lionetti E, Francavilla R, Pavone P, et al. The neurology of coeliac disease in childhood: 
what is the evidence? A systematic review and meta-analysis. Dev Med Child Neurol. 2010 52: 
700-707. 
[7]. Cakir D, Tosun A, Polat M, et al. Subclinical neurological abnormalities in children with 
celiac disease receiving a gluten-free diet. J Pediatr Gastroenterol Nutr. 2007 45: 366-369. 
[8]. Ruggieri M, Incorpora G, Polizzi A, Parano E, Spina M, Pavone P. Low prevalence of 
neurologic and psychiatric manifestations in children with gluten sensitivity. J Pediatr. 2008 
152: 244-249. 
[9]. Zelnik N, Pacht A, Obeid R, Lerner A. Range of neurologic disorders in patients with 
celiac disease. Pediatrics. 2004 113: 1672-1676. 
[10]. Ludvigsson JF, Zingone F, Tomson T, Ekbom A, Ciacci C. Increased risk of epilepsy in 
biopsy-verified celiac disease: a population-based cohort study. Neurology. 2012 78: 1401-1407. 
[11]. Gobbi G. Coeliac disease, epilepsy and cerebral calcifications. Brain Dev. 2005 27: 189-
200. 
  
[12]. Sharkey LM, Corbett G, Currie E, Lee J, Sweeney N, Woodward JM. Optimising 
delivery of care in coeliac disease - comparison of the benefits of repeat biopsy and serological 
follow-up. Aliment Pharmacol Ther. 2013 38: 1278-1291. 
[13]. Lanzini A, Lanzarotto F, Villanacci V, et al. Complete recovery of intestinal mucosa 
occurs very rarely in adult coeliac patients despite adherence to gluten-free diet. Aliment 
Pharmacol Ther. 2009 29: 1299-1308. 
[14]. Pekki H, Kurppa K, Maki M, et al. Performing routine follow-up biopsy 1 year after 
diagnosis does not affect long-term outcomes in coeliac disease. Aliment Pharmacol Ther. 2017 
45: 1459-1468. 
[15]. Rubio-Tapia A, Rahim MW, See JA, Lahr BD, Wu TT, Murray JA. Mucosal recovery 
and mortality in adults with celiac disease after treatment with a gluten-free diet. Am J 
Gastroenterol. 2010 105: 1412-1420. 
[16]. Ciacci C, Cirillo M, Cavallaro R, Mazzacca G. Long-term follow-up of celiac adults on 
gluten-free diet: prevalence and correlates of intestinal damage. Digestion. 2002 66: 178-185. 
[17]. Lebwohl B, Granath F, Ekbom A, et al. Mucosal healing and mortality in coeliac disease. 
Aliment Pharmacol Ther. 2013 37: 332-339. 
[18]. Ciclitira PJ, King AL, Fraser JS. AGA technical review on Celiac Sprue. American 
Gastroenterological Association. Gastroenterology. 2001 120: 1526-1540. 
[19]. Rostom A, Dube C, Cranney A, et al. The diagnostic accuracy of serologic tests for 
celiac disease: a systematic review. Gastroenterology. 2005 128: S38-46. 
[20]. Rubio-Tapia A, Hill ID, Kelly CP, Calderwood AH, Murray JA, American College of G. 
ACG clinical guidelines: diagnosis and management of celiac disease. American Journal of 
Gastroenterology. 2013 108: 656-676; quiz 677. 
[21]. Ludvigsson JF, Brandt L, Montgomery SM, Granath F, Ekbom A. Validation study of 
villous atrophy and small intestinal inflammation in Swedish biopsy registers. BMC 
Gastroenterol. 2009 9: 19. 
  
[22]. Oberhuber G, Granditsch G, Vogelsang H. The histopathology of coeliac disease: time 
for a standardized report scheme for pathologists. Eur J Gastroenterol Hepatol. 1999 11: 1185-
1194. 
[23]. Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the 
Swedish national inpatient register. BMC Public Health. 2011 11: 450. 
[24]. Ludvigsson JF, Montgomery SM, Ekbom A, Brandt L, Granath F. Small-intestinal 
histopathology and mortality risk in celiac disease. JAMA. 2009 302: 1171-1178. 
[25]. Ludvigsson JF, Haberg SE, Knudsen GP, et al. Ethical aspects of registry-based research 
in the Nordic countries. Clin Epidemiol. 2015 7: 491-508. 
[26]. Greco A, Rizzo MI, De Virgilio A, et al. Autoimmune epilepsy. Autoimmun Rev. 2016 
15: 221-225. 
[27]. Jackson JR, Eaton WW, Cascella NG, Fasano A, Kelly DL. Neurologic and psychiatric 
manifestations of celiac disease and gluten sensitivity. Psychiatr Q. 2012 83: 91-102. 
[28]. Caruso R, Marafini I, Sedda S, et al. Analysis of the cytokine profile in the duodenal 
mucosa of refractory coeliac disease patients. Clin Sci (Lond). 2014 126: 451-458. 
[29]. Russo F, Chimienti G, Linsalata M, Clemente C, Orlando A, Riezzo G. The 
obestatin/ghrelin ratio and ghrelin genetics in adult celiac patients before and after a gluten-free 
diet, in irritable bowel syndrome patients and healthy individuals. Eur J Gastroenterol Hepatol. 
2017 29: 160-168. 
[30]. Oztas B, Sahin D, Kir H, et al. The effect of leptin, ghrelin, and neuropeptide-Y on serum 
Tnf-Alpha, Il-1beta, Il-6, Fgf-2, galanin levels and oxidative stress in an experimental 
generalized convulsive seizure model. Neuropeptides. 2017 61: 31-37. 
[31]. Portelli J, Michotte Y, Smolders I. Ghrelin: an emerging new anticonvulsant 
neuropeptide. Epilepsia. 2012 53: 585-595. 
[32]. Valletta E, Fornaro M, Cipolli M, Conte S, Bissolo F, Danchielli C. Celiac disease and 
obesity: need for nutritional follow-up after diagnosis. Eur J Clin Nutr. 2010 64: 1371-1372. 
  
[33]. Barone M, Della Valle N, Rosania R, et al. A comparison of the nutritional status 
between adult celiac patients on a long-term, strictly gluten-free diet and healthy subjects. Eur J 
Clin Nutr. 2016 70: 23-27. 
[34]. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-
related health risk factors, 2001. JAMA. 2003 289: 76-79. 
[35]. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and 
incidence of cancer: a systematic review and meta-analysis of prospective observational studies. 
Lancet. 2008 371: 569-578. 
[36]. Gao S, Juhaeri J, Dai WS. The incidence rate of seizures in relation to BMI in UK adults. 
Obesity (Silver Spring). 2008 16: 2126-2132. 
[37]. Lebwohl B, Murray JA, Rubio-Tapia A, Green PH, Ludvigsson JF. Predictors of 
persistent villous atrophy in coeliac disease: a population-based study. Aliment Pharmacol Ther. 
2014 39: 488-495. 
[38]. Smedby KE, Akerman M, Hildebrand H, Glimelius B, Ekbom A, Askling J. Malignant 
lymphomas in coeliac disease: evidence of increased risks for lymphoma types other than 
enteropathy-type T cell lymphoma. Gut. 2005 54: 54-59. 
[39]. Duncan JS, Sander JW, Sisodiya SM, Walker MC. Adult epilepsy. Lancet. 2006 367: 
1087-1100. 
 
  
 TABLES 
Table 1: Characteristics of patient cohort with CD and follow-up biopsies, excluding those 
patients who had a diagnosis of epilepsy prior to their follow-up biopsy (n=7,590) 
Characteristic Number (%) 
Age at follow-up biopsy (years) 
Mean/Median/SD 
 
30.5/26.8/24.8 
0-19 3390 (45) 
20-39 1318 (17) 
40-59 1670 (22) 
 1212 (16) 
Male 2790 (37) 
Female 4800 (63) 
Interval between diagnosis and follow-up biopsy  
6 months-1 year 2010 (26) 
Between 1 and 2 years 3399 (45) 
                      2-5 years 2181 (29) 
Calendar period of follow-up biopsy  
 719 (9) 
1990-1999 2877 (38) 
 3994 (53) 
Second biopsy result  
Mucosal healing 4295 (57) 
Persistent villous atrophy 3295 (43) 
Developed epilepsy 75 (1) 
 
Mean/median/SD time between diagnosis of celiac disease and follow-up biopsy: 1.7/1.3/1.0 
years 
Mean/median/SD follow-up time (to epilepsy diagnosis, death, emigration, or December 31, 
2009): 10.2/8.9/5.97 years 
Of the 75 patients who developed a new diagnosis of epilepsy, the mean/median (SD) time from 
follow-up biopsy to epilepsy diagnosis was 7.1/6.2 (5.5) years. 
  
Table 2: Association of persistent villous atrophy with epilepsy stratified by gender, age, and 
year of celiac disease diagnosis. 
 
Stratum Number 
of events 
$GMXVWHG 
HR (95% CI) 
p value 
Overall    
Mucosal healing 45 1.0  
Persistent villous atrophy 30 0.61 (0.38-0.98) 0.04 
Gender    
Male    
Mucosal healing 22 1.0  
Persistent villous atrophy 8 0.35 (0.15-0.80) 0.01 
Female    
Mucosal healing 23 1.0  
Persistent villous atrophy 22 0.85 (0.46-1.57) 0.2620 
Age at follow-up biopsy 
 
   
<20    
Mucosal healing 25 1.0  
Persistent villous atrophy 14 0.61 (0.30-1.25) 0.1745 
20-39    
Mucosal healing 4 1.0  
Persistent villous atrophy 2 0.77 (0.14-4.36) 0.7669 
40-59    
Mucosal healing 8 1.0  
Persistent villous atrophy 7 0.61 (0.21-1.80) 0.7934 
    
Mucosal healing 8 1.0  
Persistent villous atrophy 7 0.66 (0.23-1.87) 0.4362 
Calendar Year    
1989 and before    
Mucosal healing 6 1.0  
Persistent villous atrophy 5 0.29 (0.09-1.00) 0.0503 
1990-1999    
Mucosal healing 21 1.0  
Persistent villous atrophy 19 0.66 (0.36-1.24) 0.1987 
2000 and after    
Mucosal healing 18 1.0  
Persistent villous atrophy 6 0.75 (0.28-1.96) 0.5508 
 
 Hazard Ratios (HR) are adjusted for patient age, gender, calendar period of diagnosis, 
education, and duration of celiac disease at the time of follow-up biopsy. 
